Title
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease
Authoring Organization
Publication Month/Year
November 15, 2021
Last Updated Month/Year
December 18, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
To review the current evidence on the options available for initiating dopaminergic treatment of motor symptoms in early-stage Parkinson disease and provide recommendations to clinicians.
Target Patient Population
Participants with parkinsons disease in the early stages
PICO Questions
In people with early parkinsons disease, what is the comparative risk of adverse effects (specifically dyskinesia, hallucinations, and AE-related discontinuation) of levodopa vs dopamine agonists (DAs) vs monoamine oxidase type B (MAO-B) inhibitors?
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory, Long term care
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D000068079 - Motor Disorders, D010300 - Parkinson Disease, D009043 - Motor Activity, D059290 - Dopaminergic Neurons
Keywords
parkinson, Parkinson's disease, Parkinson’s disease, motor symptoms
Source Citation
Pringsheim T et al. Practice guideline summary: Dopaminergic therapy for motor symptoms in early Parkinson disease. Neurology. 2021 November 15. doi: 10.1212/WNL.0000000000012868